insulin glargine
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
Sanofi announces phase 3 study data for infantile-onset Pompe disease
Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form
Sanofi’s Cenrifki approved in Europe for secondary progressive MS without relapses
SPMS is a debilitating stage of MS where patients experience increasing levels of disability
Sanofi appoints Paulo Fontoura as Global Head of R&D
Fontoura previously held senior leadership roles at Xaira Therapeutics and Roche
Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector
It is the first anticancer treatment in the UK and globally to be administered this way and a first in multiple myeloma
CSL’s Privigen approved as measles treatment by European Commission
Cases of measles have been rising in Europe since 2023
Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes
The treatment can be used to delay the onset of clinical type 1 diabetes
EMA’s PRIME scheme launches three major new features
The scheme supports the development of treatments targeting unmet medical needs in the EU
Novo Nordisk’s Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes
The insulin is designed as an alternative to daily basal insulin
BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma
This type of cancer is the most common one diagnosed in teenagers
Novo Nordisk announces positive results for CagriSema in type 2 diabetes
CagriSema improved weight loss and blood glucose control compared to semaglutide alone across all tested doses
Sanofi announces positive results for venglustat in type 3 Gaucher disease
There are currently no approved treatments for the neurological symptoms of this disease